On Aug. 3, 2021, Vanda Pharmaceuticals announced that enrollment had closed in the ODYSSEY study comparing tradipitant and placebo in hospitalized COVID-19 pneumonia patients. Enrollment was closed because the study met the pre-defined futility criteria, indicating that the study was unlikely to succeed in its pre-specified
primary endpoint.